|
1
|
Hoff PM, Ansari R, Batist G, Cox J, Kocha
W, Kuperminc M, Maroun J, Walde D, Weaver C, Harrison E, et al:
Comparison of oral capecitabine versus intravenous fluorouracil
plus leucovorin as first-line treatment in 605 patients with
metastatic colorectal cancer: Results of a randomized phase III
study. J Clin Oncol. 19:2282–2292. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Shiga T and Hiraide M: Cardiotoxicities of
5-fluorouracil and other fluoropyrimidines. Curr Treat Options
Oncol. 21:272020. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Polk A, Vaage-Nilsen M, Vistisen K and
Nielsen DL: Cardiotoxicity in cancer patients treated with
5-fluorouracil or capecitabine: A systematic review of incidence,
manifestations and predisposing factors. Cancer Treat Rev.
39:974–984. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Becker K, Erckenbrecht JF, Häussinger D
and Frieling T: Cardiotoxicity of the antiproliferative compound
fluorouracil. Drugs. 57:475–484. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Deboever G, Hiltrop N, Cool M and
Lambrecht G: Alternative treatment options in colorectal cancer
patients with 5-fluorouracil- or capecitabine-induced
cardiotoxicity. Clin Colorectal Cancer. 12:8–14. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Polk A, Vistisen K, Vaage-Nilsen M and
Nielsen DL: A systematic review of the pathophysiology of
5-fluorouracil-induced cardiotoxicity. BMC Pharmacol Toxicol.
15:472014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Südhoff T, Enderle MD, Pahlke M, Petz C,
Teschendorf C, Graeven U and Schmiegel W: 5-Fluorouracil induces
arterial vasocontractions. Ann Oncol. 15:661–664. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Jensen SA, Hasbak P, Mortensen J and
Sørensen JB: Fluorouracil induces myocardial ischemia with
increases of plasma brain natriuretic peptide and lactic acid but
without dysfunction of left ventricle. J Clin Oncol. 28:5280–5286.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Arellano M, Malet-Martino M, Martino R and
Gires P: The anti-cancer drug 5-fluorouracil is metabolized by the
isolated perfused rat liver and in rats into highly toxic
fluoroacetate. Br J Cancer. 77:79–86. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Depetris I, Marino D, Bonzano A, Cagnazzo
C, Filippi R, Aglietta M and Leone F: Fluoropyrimidine-induced
cardiotoxicity. Crit Rev Oncol Hematol. 124:1–10. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Van Cutsem E, Hoff PM, Blum JL, Abt M and
Osterwalder B: Incidence of cardiotoxicity with the oral
fluoropyrimidine capecitabine is typical of that reported with
5-fluorouracil. Ann Oncol. 13:484–485. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Cao RY, Li Q, Miao Y, Zhang Y, Yuan W, Fan
L, Liu G, Mi Q and Yang J: The emerging role of MicroRNA-155 in
cardiovascular diseases. Biomed Res Int. 2016:98692082016.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Navickas R, Gal D, Laucevičius A,
Taparauskaitė A, Zdanytė M and Holvoet P: Identifying circulating
microRNAs as biomarkers of cardiovascular disease: A systematic
review. Cardiovasc Res. 111:322–337. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Rigaud VO, Ferreira LR, Ayub-Ferreira SM,
Ávila MS, Brandão SM, Cruz FD, Santos MH, Cruz CB, Alves MS, Issa
VS, et al: Circulating miR-1 as a potential biomarker of
doxorubicin-induced cardiotoxicity in breast cancer patients.
Oncotarget. 8:6994–7002. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Van Cutsem E, Cervantes A, Adam R, Sobrero
A, Van Krieken JH, Aderka D, Aranda Aguilar E, Bardelli A, Benson
A, Bodoky G, et al: ESMO consensus guidelines for the management of
patients with metastatic colorectal cancer. Ann Oncol.
27:1386–1422. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Argilés G, Tabernero J, Labianca R,
Hochhauser D, Salazar R, Iveson T, Laurent-Puig P, Quirke P,
Yoshino T, Taieb J, et al: Localised colon cancer: ESMO clinical
practice guidelines for diagnosis, treatment and follow-up. Ann
Oncol. 31:1291–1305. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Sonoda T, Matsuzaki J, Yamamoto Y, Sakurai
T, Aoki Y, Takizawa S, Niida S and Ochiya T: Serum MicroRNA-based
risk prediction for stroke. Stroke. 50:1510–1518. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhang Y, Zhang L, Wang Y, Ding H, Xue S,
Qi H and Li P: MicroRNAs or long noncoding RNAs in diagnosis and
prognosis of coronary artery disease. Aging Dis. 10:353–366. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Jensen SA and Sørensen JB: Risk factors
and prevention of cardiotoxicity induced by 5-fluorouracil or
capecitabine. Cancer Chemother Pharmacol. 58:487–493. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kosmas C, Kallistratos MS, Kopterides P,
Syrios J, Skopelitis H, Mylonakis N, Karabelis A and Tsavaris N:
Cardiotoxicity of fluoropyrimidines in different schedules of
administration: A prospective study. J Cancer Res Clin Oncol.
134:75–82. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Eskilsson J and Albertsson M: Failure of
preventing 5-fluorouracil cardiotoxicity by prophylactic treatment
with verapamil. Acta Oncol. 29:1001–1003. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Peng J, Dong C, Wang C, Li W, Yu H, Zhang
M, Zhao Q, Zhu B, Zhang J, Li W, et al: Cardiotoxicity of
5-fluorouracil and capecitabine in Chinese patients: A prospective
study. Cancer Commun (Lond). 38:222018. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Leger KJ, Leonard D, Nielson D, de Lemos
JA, Mammen PP and Winick NJ: Circulating microRNAs: Potential
markers of cardiotoxicity in children and young adults treated with
anthracycline chemotherapy. J Am Heart Assoc. 6:e0046532017.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Lindholm EM, Ragle Aure M, Haugen MH,
Kleivi Sahlberg K, Kristensen VN, Nebdal D, Børresen-Dale AL,
Lingjaerde OC and Engebraaten O: miRNA expression changes during
the course of neoadjuvant bevacizumab and chemotherapy treatment in
breast cancer. Mol Oncol. 13:2278–2296. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Offer SM, Butterfield GL, Jerde CR, Fossum
CC, Wegner NJ and Diasio RB: microRNAs miR-27a and miR-27b directly
regulate liver dihydropyrimidine dehydrogenase expression through
two conserved binding sites. Mol Cancer Ther. 13:742–751. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Morel A, Boisdron-Celle M, Fey L, Soulie
P, Craipeau MC, Traore S and Gamelin E: Clinical relevance of
different dihydropyrimidine dehydrogenase gene single nucleotide
polymorphisms on 5-fluorouracil tolerance. Mol Cancer Ther.
5:2895–2904. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Gokare P, Finnberg NK, Abbosh PH, Dai J,
Murphy ME and El-Deiry WS: P53 represses pyrimidine catabolic gene
dihydropyrimidine dehydrogenase (DPYD) expression in response to
thymidylate synthase (TS) targeting. Sci Rep. 7:97112017.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Saif MW, Hachem H, Purvey S, Hamal R,
Zhang L, Siddiqui NS, Godara A and Diasio RB: Pharmacogenetic
variants in the DPYD and TYMS genes are clinically significant
predictors of fluoropyrimidine toxicity: Are we ready for use in
our clinical practice. Arch Pharmacol Ther. 2:6–8. 2020.PubMed/NCBI
|
